Results 161 to 170 of about 7,787 (204)
Some of the next articles are maybe not open access.
Elucidating the complexation of nifurtimox with cyclodextrins
Journal of Molecular Liquids, 2023Fil: Arrua, Eva Carolina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigación y Desarrollo en Materiales Avanzados y Almacenamiento de Energía de Jujuy - Universidad Nacional de Jujuy. Centro de Investigación y Desarrollo en Materiales Avanzados y Almacenamiento de Energía de Jujuy - Gobierno de la Provincia de Jujuy ...
Giselle Bedogni +4 more
openaire +2 more sources
Further trials of nifurtimox in mucocutaneous leishmaniasis
Transactions of the Royal Society of Tropical Medicine and Hygiene, 1981At a dosage level of 8 to 10 mg/kg body-weight daily for 120 days nifurtimox was associated with clinical healing of cutaneous leishmaniasis in five of eight patients. At a dosage level of 20 mg/kg body-weight daily for 10 days in six of 10 patients the skin ulcer healed. Results and the reasons why both schemes are impracticable are briefly discussed.
M F, Guerra +3 more
openaire +2 more sources
Antiparasitic Prodrug Nifurtimox: Revisiting its Activation Mechanism
Future Microbiology, 2011EVALUATION OF: Hall BS, Bot C, Wilkinson SR. Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites. J. Biol. Chem. 286, 13088-13095 (2011). The prodrug nifurtimox has been one of the pharmacologic alternatives to treat Chagas disease and currently forms part of a combinational therapy to treat West African
Hugo, Cerecetto, Mercedes, González
openaire +2 more sources
Lipid alterations induced by Nifurtimox in Trypanosoma cruzi
Molecular and Biochemical Parasitology, 1986The influence of growth in the presence of nifurtimox on total lipids of Trypanosoma cruzi epimastigotes was determined. Nifurtimox-treated organisms showed greater amounts of unsaturated fatty acids as compared with control cells. 18:2 was the major component in the total esterified lipid fraction.
E, Barreto-Bergter +2 more
openaire +2 more sources
Nifurtimox in the treatment of South American leishmaniasis
Transactions of the Royal Society of Tropical Medicine and Hygiene, 1979A trial of Nifurtimox (Lampit) in 26 patients with mucocutaneous leishmaniasis is reported. 13 patients with cutaneous lesions and 13 patients with mucosal disease were treated with a daily oral divided dose of 10 mg/kg body-weight for 30 days. 46% of the cutaneous cases and only 15% of the mucosal cases apparently responded to this regimen during at ...
P D, Marsden +4 more
openaire +2 more sources
Nifurtimox Plus Pyrimethamine for Treatment of Murine Toxoplasmosis
The Journal of Parasitology, 1998In the search for novel antitoxoplasmic agents, we evaluated the efficacy of nifurtimox (3-methyl-4[5'-nitrofurfurylidene-amino]-tetrahydroe-4H-1,4- thiazine-1,1-dioxide), an antiprotozoal drug effective against trypanosomiasis, in an experimental model of acute toxoplasmosis in mice.
L, Aguirre-Cruz, O, Velasco, J, Sotelo
openaire +2 more sources
Nifurtimox (Lampit) for Chagas Disease
The Medical Letter on Drugs and TherapeuticsThe FDA has approved the nitrofuran antiprotozoal drug nifurtimox (Lampit – Bayer) for treatment of Chagas disease (American trypanosomiasis) in children who weigh ≥2.5 kg. Nifurtimox was previously available in the US only through a CDC-sponsored Investigational New Drug (IND) program.
openaire +2 more sources
Conformational analysis and spectroscopic properties of antichagasic nifurtimox
Spectrochimica Acta Part A: Molecular and Biomolecular SpectroscopyConsidering the health relevance of Chagas' disease, recent research efforts have focused on developing more efficient drug delivery systems containing nifurtimox (NFX). This paper comprehensively investigates NFX through conformational analysis and spectroscopic characterization.
Idejan P. Gross +7 more
openaire +2 more sources